Ablynx data on RA candidate boosts partnering
This article was originally published in Scrip
The awaited 24-week final analysis of the Phase II study of Ablynx's IL-6 receptor inhibitor nanobody ALX-0061, for rheumatoid arthritis has confirmed the interim proof-of-concept data released last October (scripintelligence.com, 4 October 2012). The data will add fuel to Ablynx's partnering discussions for the program.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.